Del Rosso-Armstrong-Lebwohl-Brownstone

Download our free JAK/TYK2 Inhibitors for Dermatology Quick Reference Charts

JAK +Vaccines chart icon_transparent.png

JAK 1–3 & TYK2 Inhibitors in Dermatology

Brownstone-Lebwohl

Download our free biologics Quick Reference Chart for dermatology

Biologic chart icon_transparent.png

Biologic Medications for Psoriasis, HS, AD, PN, CSU, and BP

Download our free Quick Reference Chart for Topical Non-steroidal and Fixed Combination Therapies

Topical Non-steroidal Therapies icon_transparent.png

Topical Non-steroidal Therapies

Download our free Quick Reference Chart for Vaccines and Systemic Therapies Chart

Vaccines and Systemic Therapies

by Dr. Mark Lebwohl

Check out our free Generalized Idiopathic Pruritus Questionnaire

Generalized Idiopathic Pruritus Questionnaire icon_transparent.png

Generalized Idiopathic Pruritus Questionnaire

Anzupgo (delgocitinib) cream 2% is a topical pan–Janus kinase (JAK) inhibitor for the treatment of moderate-to-severe chronic hand eczema (CHE) in adults who have had an inadequate response to topical corticosteroids or for whom such treatments are not advisable. It is currently the only therapy with a specific FDA-approved indication for CHE.&nbsp;Anzupgo works by inhibiting JAK1, JAK2, JAK3, and tyrosine kinase 2, which are key components of the JAK-STAT signaling pathway. This pathway regulates the activity of multiple pro-inflammatory cytokines involved in skin inflammation. By blocking JAK activation, Anzupgo reduces downstream STAT signaling, which in turn decreases the expression of cytokine-responsive genes that drive inflammatory responses in the skin.&nbsp;The recommended dosing for Anzupgo is twice-daily application to affected areas of the hands and wrists only. The total amount applied should not exceed 30 grams over a 2-week period or 60 grams per month. The medication is not intended for use on other parts of the body and should not be used in combination with other JAK inhibitors or potent immunosuppressive therapies.&nbsp;In clinical trials, Anzupgo demonstrated a safety profile generally comparable to vehicle. Adverse reactions occurring in ≤ 1% of patients included application site pain, paresthesia, erythema, pruritus, and bacterial skin infections. Instances of leukopenia and neutropenia were also reported. Most adverse events were mild or moderate in intensity. For dermatologists, Anzupgo offers a new therapeutic option for a population with limited alternatives. Chronic hand eczema can be persistent, painful, and resistant to conventional treatments. With its targeted mechanism of action and topical formulation, Anzupgo provides a nonsteroidal alternative designed specifically for this condition, helping to fill a longstanding gap in the management of moderate-to-severe CHE.

Learn more about Anzupgo

Latest research

ANZUPGO.png

Anzupgo (delgocitinib) 

Leqselvi (deuruxolitinib) is an oral Janus kinase (JAK) inhibitor indicated for the treatment of adults with severe alopecia areata (AA). The recommended dosage is 8 mg taken orally twice daily.Leqselvi works by targeting the JAK-STAT signaling pathway, which plays a central role in inflammatory and autoimmune processes implicated in alopecia areata. Specifically, deuruxolitinib inhibits the phosphorylation and activation of STAT proteins by selectively targeting JAK1 and JAK2. This broad inhibitory profile may contribute to its efficacy in reducing autoimmune-mediated hair follicle disruption.In clinical studies, the most common adverse reactions reported (≥1%) included headache, acne, nasopharyngitis, elevated creatine phosphokinase, hyperlipidemia, fatigue, weight gain, lymphopenia, thrombocytosis, anemia, skin and soft tissue infections, neutropenia, and herpes infections.Like other systemic JAK inhibitors, Leqselvi carries a boxed warning for serious risks including infections, malignancy, major adverse cardiovascular events (MACE), thrombosis, and increased all-cause mortality. It is not recommended for use in combination with other JAK inhibitors, biologic immunomodulators, cyclosporine, or other potent immunosuppressants.For dermatologists, Leqselvi offers another systemic option for patients with severe AA, particularly those who may not have responded to or tolerated other JAK inhibitors. The twice-daily oral dosing may require added patient counseling compared to once-daily alternatives. Given the class-wide safety considerations, careful patient selection, baseline laboratory evaluation, and ongoing monitoring are critical. &nbsp;Studies suggest that Leqselvi may achieve substantial hair regrowth by 24 weeks, making it a promising addition to the therapeutic landscape for this condition.

Learn more about Leqselvi

LEQSELVI_product.jpg

Leqselvi (deuruxolitinib)

Adbry (tralokinumab-ldrm) is an interleukin-13 (IL-13) antagonist biologic therapy administered by subcutaneous injection, indicated for the treatment of moderate-to-severe atopic dermatitis (AD) in adults and pediatric patients aged 12 years and older whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.

Adbry selectively binds to IL-13, a key cytokine involved in the inflammatory response of AD, blocking its interaction with IL-13 receptors to reduce inflammation and skin barrier dysfunction. The package insert specifically mentions the following adverse events: upper respiratory tract infections, conjunctivitis, injection site reactions, and eosinophilia. Patients should be monitored for signs of hypersensitivity reactions, conjunctivitis, and keratitis. Live vaccines should be avoided during treatment with Adbry. It can be incorporated into a broader treatment strategy for atopic dermatitis, offering a targeted approach for patients who have not responded to topical therapies. Adbry may be used as monotherapy or in combination with topical corticosteroids, providing flexibility in managing both acute and chronic symptoms. Its selective inhibition of IL-13, without affecting IL-4, differentiates it from other biologics in the AD treatment landscape, making it a valuable long-term therapy option for eligible patients.

Adbry (tralokinumab-ldrm) is an interleukin-13 (IL-13) antagonist biologic therapy administered by subcutaneous injection, indicated for the treatment of moderate-to-severe atopic dermatitis (AD) in adults and pediatric patients aged 12 years and older whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.Adbry selectively binds to IL-13, a key cytokine involved in the inflammatory response of AD, blocking its interaction with IL-13 receptors to reduce inflammation and skin barrier dysfunction. The package insert specifically mentions the following adverse events: upper respiratory tract infections, conjunctivitis, injection site reactions, and eosinophilia. Patients should be monitored for signs of hypersensitivity reactions, conjunctivitis, and keratitis. Live vaccines should be avoided during treatment with Adbry. It can be incorporated into a broader treatment strategy for atopic dermatitis, offering a targeted approach for patients who have not responded to topical therapies. Adbry may be used as monotherapy or in combination with topical corticosteroids, providing flexibility in managing both acute and chronic symptoms. Its selective inhibition of IL-13, without affecting IL-4, differentiates it from other biologics in the AD treatment landscape, making it a valuable long-term therapy option for eligible patients.

Learn more about Adbry

adbry.png

Adbry (tralokinumab-ldrm)

Ebglyss (lebrikizumab) is an IL-13 antagonist indicated for the treatment of moderate-to-severe atopic dermatitis (AD) in adult and pediatric patients ages 12 and older who weigh ≥40 kg. It is administered by subcutaneous injection with a dosing regimen that can be tailored to patient needs.
Ebglyss selectively binds to IL-13, a key cytokine implicated in the pathophysiology of AD. By binding to IL-13 with high affinity and slow dissociation, Ebglyss prevents the formation of the IL-4R⍺/IL-13R⍺1 receptor complex and inhibits downstream IL-13 signaling. This targeted mechanism addresses the inflammation and skin barrier dysfunction central to AD.
The label for Ebgyss specifically mentions the following adverse reactions (≥1%): conjunctivitis, injection site reactions, and herpes zoster.
Ebglyss can be effectively incorporated into treatment plans for patients with moderate-to-severe AD who have not achieved adequate control with topical therapies or other systemic agents. It can be used as monotherapy or alongside topical treatments, providing flexibility in addressing both acute and chronic disease management.
Ebglyss stands out for its highly specific inhibition of IL-13, offering a more focused approach compared to agents that target multiple cytokines. Its favorable safety profile and targeted action make it suitable for long-term use in eligible patients. Ebglyss has demonstrated substantial efficacy in improving disease severity and patient quality of life, making it a valuable option in the expanding AD treatment landscape.

Ebglyss (lebrikizumab) is an IL-13 antagonist indicated for the treatment of moderate-to-severe atopic dermatitis (AD) in adult and pediatric patients ages 12 and older who weigh ≥40 kg. It is administered by subcutaneous injection with a dosing regimen that can be tailored to patient needs. Ebglyss selectively binds to IL-13, a key cytokine implicated in the pathophysiology of AD. By binding to IL-13 with high affinity and slow dissociation, Ebglyss prevents the formation of the IL-4R⍺/IL-13R⍺1 receptor complex and inhibits downstream IL-13 signaling. This targeted mechanism addresses the inflammation and skin barrier dysfunction central to AD. The label for Ebgyss specifically mentions the following adverse reactions (≥1%): conjunctivitis, injection site reactions, and herpes zoster. Ebglyss can be effectively incorporated into treatment plans for patients with moderate-to-severe AD who have not achieved adequate control with topical therapies or other systemic agents. It can be used as monotherapy or alongside topical treatments, providing flexibility in addressing both acute and chronic disease management. Ebglyss stands out for its highly specific inhibition of IL-13, offering a more focused approach compared to agents that target multiple cytokines. Its favorable safety profile and targeted action make it suitable for long-term use in eligible patients. Ebglyss has demonstrated substantial efficacy in improving disease severity and patient quality of life, making it a valuable option in the expanding AD treatment landscape.

Learn more about Ebglyss

ebglyss.jpg

Ebglyss (lebrikizumab) 

Rinvoq (upadacitinib) is an oral, once-daily Janus kinase (JAK) inhibitor. In dermatology, it is indicated for the treatment of adults and pediatric patients 12 years and older with moderate to severe atopic dermatitis that is not adequately controlled with other systemic drugs and the treatment of adults and pediatric patients 2 years and older with active psoriatic arthritis who have had an inadequate response or intolerance to one or more TNF blockers.
It is also indicated for the treatment of rheumatoid arthritis, ulcerative colitis, Crohn’s disease, active ankylosing spondylitis, active nonradiographic axial spondyloarthritis, and active polyarticular juvenile idiopathic arthritis.
Rinvoq works by selectively inhibiting JAK1, with greater potency than JAK2, JAK3 and TYK2. By targeting the JAK-STAT signaling pathway, Rinvoq blocks the recruitment, phosphorylation, and activation of STATs, preventing pro-inflammatory cytokine signaling and inhibiting pro-inflammatory processes.
For atopic dermatitis, the package insert specifically mentions the following adverse reactions (≥ 1%): upper respiratory tract infections, acne, herpes simplex, headache, blood creatine phosphokinase increase, cough, hypersensitivity, folliculitis, nausea, abdominal pain, pyrexia, increased weight, herpes zoster, influenza, fatigue, neutropenia, myalgia, and influenza-like illness.
For psoriatic arthritis, it mentions the following adverse reactions (≥ 1%): upper respiratory tract infections, herpes zoster, herpes simplex, bronchitis, nausea, cough, pyrexia, acne, and headache.
Rinvoq is not recommended for use in combination with other JAK inhibitors, biologic immunomodulators, or other immunosuppressants.
Rinvoq offers a targeted oral option for patients with moderate-to-severe atopic dermatitis or active psoriatic arthritis who have not achieved adequate control with existing therapies. It can be integrated into treatment plans as a standalone systemic therapy. By addressing the JAK-STAT pathway, Rinvoq helps reduce inflammation and improve disease control, offering an effective option for patients living with refractory disease.

Rinvoq (upadacitinib) is an oral, once-daily Janus kinase (JAK) inhibitor. In dermatology, it is indicated for the treatment of adults and pediatric patients 12 years and older with moderate to severe atopic dermatitis that is not adequately controlled with other systemic drugs and the treatment of adults and pediatric patients 2 years and older with active psoriatic arthritis who have had an inadequate response or intolerance to one or more TNF blockers. It is also indicated for the treatment of rheumatoid arthritis, ulcerative colitis, Crohn’s disease, active ankylosing spondylitis, active nonradiographic axial spondyloarthritis, and active polyarticular juvenile idiopathic arthritis. Rinvoq works by selectively inhibiting JAK1, with greater potency than JAK2, JAK3 and TYK2. By targeting the JAK-STAT signaling pathway, Rinvoq blocks the recruitment, phosphorylation, and activation of STATs, preventing pro-inflammatory cytokine signaling and inhibiting pro-inflammatory processes. For atopic dermatitis, the package insert specifically mentions the following adverse reactions (≥ 1%): upper respiratory tract infections, acne, herpes simplex, headache, blood creatine phosphokinase increase, cough, hypersensitivity, folliculitis, nausea, abdominal pain, pyrexia, increased weight, herpes zoster, influenza, fatigue, neutropenia, myalgia, and influenza-like illness. For psoriatic arthritis, it mentions the following adverse reactions (≥ 1%): upper respiratory tract infections, herpes zoster, herpes simplex, bronchitis, nausea, cough, pyrexia, acne, and headache. Rinvoq is not recommended for use in combination with other JAK inhibitors, biologic immunomodulators, or other immunosuppressants. Rinvoq offers a targeted oral option for patients with moderate-to-severe atopic dermatitis or active psoriatic arthritis who have not achieved adequate control with existing therapies. It can be integrated into treatment plans as a standalone systemic therapy. By addressing the JAK-STAT pathway, Rinvoq helps reduce inflammation and improve disease control, offering an effective option for patients living with refractory disease.

Learn more about Rinvoq

RINVOQProductImage_1717175385716-HR.jpg

Rinvoq (upadacitinib) 

VTAMA (tapinarof) cream 1% is an aryl hydrocarbon receptor (AhR) agonist indicated for the topical treatment of plaque psoriasis in adults and atopic dermatitis in adults and pediatric patients 2 years and older. VTAMA cream is applied as a thin layer to affected areas once daily.
The active ingredient, tapinarof, works by supporting natural pathways regulated by AhR receptors. This includes suppressing Th17 cell differentiation and production of key cytokines, such as IL-17 and IL-22, which play a central role in the inflammatory process of psoriasis; upregulating skin barrier proteins to help restore skin barrier function; and inducing the Nrf2 transcription factor pathway to increase antioxidant activity.
VTAMA does not have any contraindications. For plaque psoriasis, the package insert specifically mentions the following adverse reactions (incidence ≥ 1%) in patients treated with VTAMA cream: folliculitis, nasopharyngitis, contact dermatitis, headache, pruritus, and influenza. For atopic dermatitis, it mentions upper respiratory tract infection, folliculitis, lower respiratory tract infection, headache, asthma, vomiting, ear infection, pain in extremities, and abdominal pain.
As a nonsteroidal topical treatment, VTAMA offers an alternative to traditional corticosteroids for the management of plaque psoriasis and atopic dermatitis. Its unique mechanism of action and absence of contraindications make it a potential option for long-term use. VTAMA may be used as monotherapy or in combination with systemic therapies, offering clinicians an additional choice for addressing the chronic and inflammatory nature of plaque psoriasis and atopic dermatitis.

VTAMA (tapinarof) cream 1% is an aryl hydrocarbon receptor (AhR) agonist indicated for the topical treatment of plaque psoriasis in adults and atopic dermatitis in adults and pediatric patients 2 years and older. VTAMA cream is applied as a thin layer to affected areas once daily. The active ingredient, tapinarof, works by supporting natural pathways regulated by AhR receptors. This includes suppressing Th17 cell differentiation and production of key cytokines, such as IL-17 and IL-22, which play a central role in the inflammatory process of psoriasis; upregulating skin barrier proteins to help restore skin barrier function; and inducing the Nrf2 transcription factor pathway to increase antioxidant activity. VTAMA does not have any contraindications. For plaque psoriasis, the package insert specifically mentions the following adverse reactions (incidence ≥ 1%) in patients treated with VTAMA cream: folliculitis, nasopharyngitis, contact dermatitis, headache, pruritus, and influenza. For atopic dermatitis, it mentions upper respiratory tract infection, folliculitis, lower respiratory tract infection, headache, asthma, vomiting, ear infection, pain in extremities, and abdominal pain. As a nonsteroidal topical treatment, VTAMA offers an alternative to traditional corticosteroids for the management of plaque psoriasis and atopic dermatitis. Its unique mechanism of action and absence of contraindications make it a potential option for long-term use. VTAMA may be used as monotherapy or in combination with systemic therapies, offering clinicians an additional choice for addressing the chronic and inflammatory nature of plaque psoriasis and atopic dermatitis.

Learn more about VTAMA

new_tube.png

VTAMA (tapinarof) cream 1%

Bimzelx (bimekizumab-bkzx) is a dual humanized interleukin 17A and F antagonist biologic therapy administered by subcutaneous injection. It is indicated for the treatment of adults with moderate to severe plaque psoriasis, active psoriatic arthritis, moderate to severe hidradenitis suppurativa, active nonradiographic axial spondyloarthritis with objective signs of inflammation, and active ankylosing spondylitis.
Bimzelx targets IL-17A and IL-17F, cytokines involved in inflammatory and immune processes, particularly in conditions like psoriasis and hidradenitis suppurativa. By inhibiting both IL-17A and IL-17F, Bimzelx suppresses the release of proinflammatory cytokines and chemokines. 
For psoriasis and hidradenitis suppurativa, the package insert specifically mentions the following adverse reactions: upper respiratory tract infections, oral candidiasis, headache, injection site reactions, tinea infections, gastroenteritis, Herpes simplex infections, acne, folliculitis, other candida infections, and fatigue. 
For psoriatic arthritis, it mentions upper respiratory tract infections, oral candidiasis, headache, diarrhea, and urinary tract infections. 
In clinical practice, candidiasis is likely to be one of the most encountered adverse events with Bimzelx in patients treated for psoriasis, psoriatic arthritis, or hidradenitis suppurativa.
Other notable adverse reactions include suicidal ideation and behavior, liver biochemical abnormalities, and inflammatory bowel disease. Clinicians should monitor patients closely for these events.
As with other biologics, combining Bimzelx with additional immunosuppressive therapies, such as other biologics or live vaccines, is not recommended.
Bimzelx can be used as part of a comprehensive treatment plan for dermatologic conditions, often combined with topicals to optimize patient outcomes. Its dual mechanism of action can offer an effective approach to addressing complex inflammatory pathways in psoriasis, psoriatic arthritis, and hidradenitis suppurativa. 


Bimzelx (bimekizumab-bkzx) is a dual humanized interleukin 17A and F antagonist biologic therapy administered by subcutaneous injection. It is indicated for the treatment of adults with moderate to severe plaque psoriasis, active psoriatic arthritis, moderate to severe hidradenitis suppurativa, active nonradiographic axial spondyloarthritis with objective signs of inflammation, and active ankylosing spondylitis.Bimzelx targets IL-17A and IL-17F, cytokines involved in inflammatory and immune processes, particularly in conditions like psoriasis and hidradenitis suppurativa. By inhibiting both IL-17A and IL-17F, Bimzelx suppresses the release of proinflammatory cytokines and chemokines.&nbsp;For psoriasis and hidradenitis suppurativa, the package insert specifically mentions the following adverse reactions: upper respiratory tract infections, oral candidiasis, headache, injection site reactions, tinea infections, gastroenteritis, Herpes simplex infections, acne, folliculitis, other candida infections, and fatigue.&nbsp;For psoriatic arthritis, it mentions upper respiratory tract infections, oral candidiasis, headache, diarrhea, and urinary tract infections.&nbsp;In clinical practice, candidiasis is likely to be one of the most encountered adverse events with Bimzelx in patients treated for psoriasis, psoriatic arthritis, or hidradenitis suppurativa.Other notable adverse reactions include suicidal ideation and behavior, liver biochemical abnormalities, and inflammatory bowel disease. Clinicians should monitor patients closely for these events.As with other biologics, combining Bimzelx with additional immunosuppressive therapies, such as other biologics or live vaccines, is not recommended.Bimzelx can be used as part of a comprehensive treatment plan for dermatologic conditions, often combined with topicals to optimize patient outcomes. Its dual mechanism of action can offer an effective approach to addressing complex inflammatory pathways in psoriasis, psoriatic arthritis, and hidradenitis suppurativa.&nbsp; &nbsp;

Learn more about Bimzelx

bimzelx.jpg

Bimzelx (bimekizumab-bkzx) 

Taltz (ixekizumab) is a monoclonal antibody biologic therapy administered by subcutaneous injection indicated for the treatment of moderate-to-severe plaque psoriasis in adults and pediatric patients aged 6 years and older, adults with active psoriatic disease, adults with active ankylosing spondylitis, and adults with active nonradiographic axial spondyloarthritis with objective signs of inflammation. It targets interleukin 17A, a cytokine involved in the inflammatory process of psoriasis, helping to reduce symptoms and achieve clearer skin. The package insert specifically mentions the following adverse events: injection site reaction, upper respiratory infections, nausea, and tinea infection. It is recommended to avoid combining Taltz with other immunosuppressive therapies such as other biologics or live vaccines. Taltz can be used as part of a broader treatment strategy for psoriasis, often used alongside topical or other systemic therapies to optimize patient outcomes, and is a safe and effective long-term therapy option for the treatment of psoriasis in both adults and children. 

Taltz (ixekizumab) is a monoclonal antibody biologic therapy administered by subcutaneous injection indicated for the treatment of moderate-to-severe plaque psoriasis in adults and pediatric patients aged 6 years and older, adults with active psoriatic disease, adults with active ankylosing spondylitis, and adults with active nonradiographic axial spondyloarthritis with objective signs of inflammation. It targets interleukin 17A, a cytokine involved in the inflammatory process of psoriasis, helping to reduce symptoms and achieve clearer skin. The package insert specifically mentions the following adverse events: injection site reaction, upper respiratory infections, nausea, and tinea infection. It is recommended to avoid combining Taltz with other immunosuppressive therapies such as other biologics or live vaccines. Taltz can be used as part of a broader treatment strategy for psoriasis, often used alongside topical or other systemic therapies to optimize patient outcomes, and is a safe and effective long-term therapy option for the treatment of psoriasis in both adults and children.&nbsp;

Learn more about Taltz

taltz_1.jpg

Taltz (ixekizumab) 

Opzelura cream is a topically applied JAK inhibitor indicated for the treatment of atopic dermatitis and for nonsegmental vitiligo in patients over the age of 12. The package insert contains the same boxed warnings that have been applied to oral JAK inhibitors and include warnings about malignancy, major adverse cardiovascular events, thrombosis, serious infections, and death; but there is no evidence that these are increased with topical application of Opzelura cream.  The package insert recommends against using in combination with biologics, other JAK inhibitors, or immunosuppressive drugs such as azathioprine and cyclosporine; but in clinical practice, Opzelura cream is often used in combination with other treatments for atopic dermatitis such as biologic therapies.

Opzelura cream is a topically applied JAK inhibitor indicated for the treatment of atopic dermatitis in patients 2 years and older and for nonsegmental vitiligo in patients 12 years and older. The package insert contains the same boxed warnings that have been applied to oral JAK inhibitors and include warnings about malignancy, major adverse cardiovascular events, thrombosis, serious infections, and death; but there is no evidence that these are increased with topical application of Opzelura cream. &nbsp;The package insert recommends against using in combination with biologics, other JAK inhibitors, or immunosuppressive drugs such as azathioprine and cyclosporine; but in clinical practice, Opzelura cream is often used in combination with other treatments for atopic dermatitis such as biologic therapies.

Level up your practice with our new

The most up-to-date information, quick reference charts, and essential tools for HCPs by HCPs.